Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD)

Slater, Bethany J.; Collings, Amelia T.; Dirks, Rebecca; Gould, Jon C.; Qureshi, Amrana; Juza, Ryan M.; Rodríguez-Luna, María Rita; Wunker, Claire; Kohn, Geoffrey P.; Kothari, Shanu N.; Carslon, Elizabeth; Worrell, Stephanie G.; Abou‐Setta, Ahmed M; Ansari, Mohammed; Athanasiadis, Dimitrios I.; Daly, Shaun; Dimou, Francesca; Haskins, Ivy N.; Hong, Julie A.; Krishnan, Kumar; Lidor, Anne O.; Litle, Virginia R.; Low, Donald E.; Petrick, Anthony; Soriano, Ian; Thosani, Nirav; Tyberg, Amy; Velanovich, Vic; Vilallonga, Ramón; Marks, Jeffrey M.

doi:10.1007/s00464-022-09817-3

Cited by 52 publications

(25 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…51 The limitations of using RYGB as a therapy for GERD are related to postoperative complications and inconclusive evidence of improvement in GERD. 52 In two observational studies, RYGB had a complication rate of ∼7% vs 0% in patients with fundoplication. [52][53][54] The primary benefit of RYGB is weight loss, which could increase the risk of failure in fundoplication.…”

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

“…52 In two observational studies, RYGB had a complication rate of ∼7% vs 0% in patients with fundoplication. [52][53][54] The primary benefit of RYGB is weight loss, which could increase the risk of failure in fundoplication. Studies have found mixed results on fundoplication vs RYGB in patients with obesity.…”

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

“…55,56 A recently published multi-society consensus recommended patients with a BMI ≥35 and GERD undergo RYGB or LNF for treatment of GERD. 52 Esophageal Neurostimulation (EndoStim) Laparoscopic implantation of an electrical neuromodulator into the abdominal wall with electrodes attached implanted into the EGJ is a newer treatment for GERD. The device is approved in Europe and was recently approved by the FDA.…”

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

See 2 more Smart Citations

Updates on Surgical Treatment for Gastroesophageal Reflux Disease

Kendrick

Kothari

2023

The American Surgeon™

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a common condition that is on the rise. Obesity is one risk factor that has increased in parallel with the rise of GERD. Typical symptoms include heartburn, regurgitation, dysphagia, cough, and chest pain. Patients with typical symptoms are empirically treated with proton pump inhibitors (PPIs). If the diagnosis is not clear, further evaluation is performed with endoscopy, pH monitoring, and esophageal manometry. Untreated GERD increases the risk of esophagitis, esophageal stricture, Barrett’s esophagus, and esophageal adenocarcinoma. Treatment begins with lifestyle modification and medical therapy. If these fail, surgical and endoscopic surgical techniques are available, to provide treatment, symptom relief, and reduce long-term PPI use.

show abstract

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

Section: Roux-en-y Gastric Bypass (Rygb)mentioning

confidence: 99%

See 1 more Smart Citation

Updates on Surgical Treatment for Gastroesophageal Reflux Disease

Kendrick

Kothari

2023

The American Surgeon™

View full text Add to dashboard Cite

show abstract

“…The recently published 2023 multi society consensus guideline, which included members from multiple surgical (thoracic, bariatric, and European) and endoscopy societies, recommended Stretta for GERD treatment [25]. However, outcomes data are conflicting.…”

Section: Radiofrequency Energy Treatment Of Gastroesophageal Reflux D...mentioning

confidence: 99%

The status of endoscopic therapies for gastroesophageal reflux disease

Kolb¹,

Chang

2023

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewGastroesophageal reflux disease (GERD) is exceedingly common and can significantly impact quality of life through heartburn, troublesome regurgitation, or atypical symptoms. The initial approach is conservative lifestyle changes followed by medications with escalation to antireflux surgery as needed. Endoscopic therapy may represent a bridge between pharmacotherapy and surgery and represents an appropriate option for select individuals.Recent findingsAppropriate patient selection for endoscopic antireflux therapies is critical to the success of the intervention. Candidates for endoscopic treatment with trans-oral incisionless fundoplication (TIF) include those with a small (<2 cm) or no hiatal hernia and a Hill valve grade 1 or 2. Transoral incisionless fundoplication with concomitant hiatal hernia repair (cTIF) is a safe and effective option that addresses both the crural diaphragm and gastroesophageal flap valve (GEFV).SummaryEndoscopic interventions for GERD continue to evolve and are not all created equal. Given our current understanding of the mechanisms of GERD, the TIF procedure stands out in its ability to re-create the optimal GEFV. In those patients with altered anatomy, endoscopic approaches may offer at least partial benefit.

show abstract

“…This led to the following general recommendations, although there were "sub-recommendations" in each general recommendation: The consensus has now been published in full in Surgical Endoscopy. 1 As the SSAT representatives to this conference, we each voted on the recommendations with the KQ group we were assigned. Although we agreed with much, there were several areas of disagreement.…”

mentioning

confidence: 99%

Commentary on the Multi-society Consensus Conference and Guideline on the Treatment of Gastroesophageal Reflux Disease (GERD)

Dimou

Lidor

Velanovich

2023

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) continues to be one of the most common problems encountered by physicians around the world. It is a vexing, protean disease, and given its increasing prevalence, systematic approaches to treatment are ideal to help improve symptoms, reduce longterm consequences of reflux, and reduce the financial burden associated with this disease. Recently, a multi-society consensus conference was assembled to better streamline workup and treatment recommendations in those with reflux disease. Specifically, experts from various societies collaborated and determined common clinical questions encountered with GERD and conducted a systematic review of the literature that would best answer these questions. The purpose of this editorial is to give the perspectives of this consensus by the Society for Surgery of the Alimentary Tract (SSAT) representatives to this process.The consensus conference was proposed by the incumbent president of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), Dr. Jeffrey Marks. The following societies, in addition to SSAT and SAGES, the American Society for Gastrointestinal Endoscopy (ASGE), the American Society for Metabolic and Bariatric Surgery (ASMBS), the European Association for Endoscopic Surgery (EAES), and the Society of Thoracic Surgeons (STS) agreed to participate in the consensus conference. Each conference provided senior and junior member experts in the field of GERD.

show abstract

Multi-society consensus conference and guideline on the treatment of gastroesophageal reflux disease (GERD)

Cited by 52 publications

References 178 publications

Updates on Surgical Treatment for Gastroesophageal Reflux Disease

Updates on Surgical Treatment for Gastroesophageal Reflux Disease

The status of endoscopic therapies for gastroesophageal reflux disease

Commentary on the Multi-society Consensus Conference and Guideline on the Treatment of Gastroesophageal Reflux Disease (GERD)

Contact Info

Product

Resources

About